June 12, 2019Open Access

Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy

Key Points

Key points are not available for this paper at this time.

Abstract

T cells. FAP- and CD19-4-1BBL thus represent an off-the-shelf combination immunotherapy without requiring genetic modification of effector cells for the treatment of solid and hematological malignancies.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Claus et al. (Wed,) studied this question.

synapsesocial.com/papers/6a10955d10ed65f1d0fd093f — DOI: https://doi.org/10.1126/scitranslmed.aav5989

Authors

Christina Claus

Roche (Switzerland)

Claudia Ferrara

Roche (Switzerland)

Wei Xu

Beijing VDJBio (China)

Journals

Science Translational Medicine

Actions

Institutions

University of Basel

Wake Forest University

Roche (Switzerland)

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion